10-KPeriod: FY2025

AGILENT TECHNOLOGIES, INC. Annual Report, Year Ended Oct 31, 2025

Filed December 22, 2025For Securities:A

Summary

Agilent Technologies, Inc. reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025, compared to the previous year. This growth was driven by strong performance across all segments and geographic regions, with the Life Sciences and Diagnostics Markets segment showing particular strength with an 11% increase, partly due to the acquisition of BIOVECTRA. The company's net income remained stable at $1,303 million, favorably impacted by tax benefits. Agilent continued its focus on operational efficiency, including a restructuring initiative aimed at optimizing management structure and achieving cost savings. The company also actively managed its capital through share repurchases and dividend payments, demonstrating a commitment to shareholder returns. Despite the overall positive revenue trend, the company faced headwinds such as increased tariffs and shipping costs, which impacted gross margins. Agilent is actively implementing mitigation strategies to address these pressures. The company also highlighted its ongoing investment in research and development to maintain its competitive edge and expand its product and solution portfolios. Looking forward, Agilent remains optimistic about the long-term health of its key end markets, despite some customer funding uncertainties, and anticipates continued growth through strategic investments and market expansion.

Financial Highlights

57 data points
Beta

Revenue

$6.95B

52.4% Gross Margin

Net Income

$1.30B

18.8% Net Margin

EPS (Diluted)

$4.57

Total Assets

$12.73B

Cash & Equivalents

$1.79B

Free Cash Flow

$1.15B

Financial Statements
Beta
Revenue$6.95B
Cost of Revenue$3.31B
Gross Profit$3.64B
R&D Expenses$455.00M
SG&A Expenses$1.71B
Operating Expenses$5.47B
Operating Income$1.48B
Interest Expense$112.00M
Net Income$1.30B
EPS (Basic)$4.59
EPS (Diluted)$4.57
Shares Outstanding (Basic)284.00M
Shares Outstanding (Diluted)285.00M

Key Highlights

  • 1Agilent Technologies reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025.
  • 2The Life Sciences and Diagnostics Markets segment experienced an 11% revenue increase, boosted by the BIOVECTRA acquisition.
  • 3Net income was $1,303 million, with tax benefits providing a favorable impact.
  • 4The company is undergoing a restructuring initiative to optimize its management structure and achieve cost savings.
  • 5Agilent returned capital to shareholders through share repurchases totaling $425 million and dividend payments of $282 million in fiscal year 2025.
  • 6Gross margins were impacted by tariffs and shipping costs, leading Agilent to implement mitigation strategies.
  • 7The company continues to invest in research and development to drive innovation and maintain its market position.

Frequently Asked Questions

Agilent Technologies reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025, compared to the prior year. Net income remained strong at $1,303 million, supported by tax benefits.

The Life Sciences and Diagnostics Markets segment was the primary growth driver, with an 11% revenue increase. This growth was significantly influenced by the acquisition of BIOVECTRA, which contributed approximately 5 percentage points. The Agilent CrossLab segment also saw a 6% revenue increase, while the Applied Markets segment experienced a more modest 1% growth.

Agilent faced increased tariffs and shipping costs, which negatively impacted gross margins. To mitigate these pressures, the company is implementing strategies such as supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives. They also noted that continued funding and resource pressure on U.S. federal government agencies and their customers impacted business.

In fiscal year 2025, Agilent repurchased approximately $425 million worth of its common stock under its repurchase programs and paid $282 million in cash dividends to shareholders, demonstrating a commitment to enhancing shareholder value.